Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer
Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · Feb 8, 2025
Trial Information
Current as of April 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a new imaging test called [18F] PSMA-1007, which helps doctors better understand and stage prostate cancer at its initial diagnosis. The goal is to see how well this new test works in real-life situations, especially for patients with high-risk prostate cancer. By gathering detailed information during this study, researchers hope to improve future use of this test and even explore how artificial intelligence can help in analyzing the results.
To participate, men aged 18 and older who are about to have a PSMA-1007 PET/CT scan for their first diagnosis of prostate cancer may be eligible. Participants will need to give their consent to join the study. It’s important to note that if a patient has technical issues during their scan that affect the images, they may not be able to participate. Overall, this trial aims to enhance the way prostate cancer is diagnosed and managed, making it easier for doctors to provide the best care for their patients.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • \> 18 years
- • Planned \[18F\]PSMA-1007 PET/CT examination in patients with a first diagnosis of prostate cancer
- • Informed consent
- Exclusion Criteria:
- • - Examinations with limited assessability due to technical errors, such as imaging artifacts.
About Heinrich Heine University, Duesseldorf
Heinrich-Heine University Düsseldorf is a leading academic institution dedicated to advancing medical research and education. Renowned for its innovative approach to healthcare and interdisciplinary collaboration, the university plays a pivotal role in clinical trials aimed at improving patient outcomes and translating scientific discoveries into clinical practice. With a robust infrastructure and a commitment to ethical standards, Heinrich-Heine University fosters an environment that supports cutting-edge research initiatives, contributing significantly to the advancement of medical knowledge and therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Duesseldorf, Nrw, Germany
Patients applied
Trial Officials
Frederik Lars Giesel, Prof. Dr., Medical Doctor
Study Chair
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported